Imugene Ltd has released a press release.
FDA clears Imugene IND for onCARlytics first-in-class study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- onCARlytics with ARTEMIS T cells show anti-tumour activity
- onCARlytics with Artemis T cells abstract presented at ASGCT
- Imugene receives $12.6m R&D tax refund
- Imugene Images and Follows CHECKVacc in TNBC Patients
- First patients dosed in IT & IV cohort 3 of VAXINIA trial
Later from Imugene
- Imugene secures IND approval for first-in-class onCARlytics trial
- Imugene doses first combination patient in PD1-Vaxx trial
- Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
- Imugene PD1-Vaxx patent extended to 2040
- HER-Vaxx induced antibodies correlated with tumour reduction
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene